Monocyte-derived dendritic cells: a potential target for therapy in multiple sclerosis (MS)

M.E. Duddy, Glenn Dickson, Stanley Hawkins, Marilyn Armstrong

Research output: Contribution to journalArticlepeer-review

19 Citations (Scopus)


Monocytes can differentiate into dendritic cells (DC), cells with a pivotal role in both protective immunity and tolerance. Defects in the maturation or function of DC may be important in the development of autoimmune disease. We sought to establish if there were differences in the cytokine (granulocyte-macrophage colony-stimulating factor and IL-4)-driven maturation of monocytes to DC in patients with MS and whether drugs used to treat MS affected this process in vitro. We have demonstrated that there is no defect in the ability of magnetic activated cell sorting (MACS)-purified monocytes from patients with MS to differentiate to DC, but equally they show no tendency to acquire a DC phenotype without exogenous cytokines. Interferon-beta1a prevents the acquisition of a full DC phenotype as determined by light and electron microscopy and by flow cytometry. Methylprednisolone not only prevents the development of monocyte-derived DC but totally redirects monocyte differentiation towards a macrophage phenotype. Evidence is evolving for a role for DC in central nervous system immunity, either within the brain or in cervical lymph nodes. The demonstrated effect of both drugs on monocyte differentiation may represent an important site for immune therapy in MS.
Original languageEnglish
Pages (from-to)280-287
Number of pages8
JournalClinical and Experimental Immunology
Issue number2
Publication statusPublished - 2001

ASJC Scopus subject areas

  • Immunology


Dive into the research topics of 'Monocyte-derived dendritic cells: a potential target for therapy in multiple sclerosis (MS)'. Together they form a unique fingerprint.

Cite this